- Approval makes Xolair the only biologic for children ages six and up with uncontrolled allergic asthma
- Asthma is one of the most common long-term diseases in children, affecting about 6.3 million people younger than 18 in the U.S.
- More than 200,000 allergic asthma patients have been treated with Xolair since its approval in 2003 for people 12 years and older3
Catalyst
Slingshot members are tracking this event:
FDA Approves Genentech’s Xolair (omalizumab) for Allergic Asthma in Children
Do you think this event is important to the companies below? How will it affect their stock price?
Related Companies | Importance
|
Impact on Stocks
|
||||
---|---|---|---|---|---|---|
RHHBY | Community voting in process |
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 07, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Omalizumab, Xolair, Allergic Asthma